Navigation Links
Kendle Expands Asia/Pacific Operations with Opening of Additional Office in India
Date:1/14/2009

CINCINNATI, Jan. 14 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced the opening of a second office in western India in the city of Ahmedabad, further expanding its presence in the country and executing on its plans for continued growth in the Asia/Pacific region. Kendle has operated in New Delhi, India since 2004 and is targeting additional expansion in India in 2009 to meet customer needs.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO )

"Expansion in the Asia/Pacific region, and India in particular, is essential to our continued success as a top global CRO," said Candace Kendle, PharmD, Chairman and CEO. "Our increased presence and capacity in the region will allow us to better meet the needs of our customers who are seeking to capitalize on India's cost-effective, yet high-quality clinical research capabilities to develop their compounds. Our expansion into Ahmedabad is another step in our continued development of a best-in-class infrastructure throughout Asia."

Kendle's India operations provide customers access to the full spectrum of early and late stage clinical development services conducted by staff experienced in running all phases of trials across all therapeutic areas. The new Ahmedabad office builds on Kendle's already strong presence in New Delhi, offering increased efficiencies and geographic coverage and providing access to the talent pool in the western part of the country.

Kendle's expansion in India reflects the growing importance of the country to the global clinical research market. With more than one billion people, a growing and improving research infrastructure, an efficient and evolving regulatory setting, favorable intellectual property laws, a large pool of medical professionals and established research credentials, India is quickly becoming a world power in clinical research. Analysts estimate that by 2011 as many as 15 percent of all global trials will be conducted in India.

Kendle's office in Ahmedabad is located at Kendle India Private Limited, B/901, Safal Pegasus, 100 Feet Road, Near AUDA Garden, Prahalad Nagar, Ahmedabad - 380051, Gujarat, India. In addition to its India locations Kendle currently operates offices in the Asia/Pacific region in Beijing, Hong Kong and Shanghai, China; Singapore; and Sydney and Melbourne, Australia.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services, we offer experience spanning 99 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Kendle was recognized by FORTUNE magazine as one of the 100 fastest-growing companies in the United States for 2008. The company also has been recognized as the "Top CRO to Work With" in the CenterWatch 2007 survey of U.S. investigative sites and among the "Top CROs in Europe" in the 2008 survey of European sites.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com .

Certain statements contained in this press release may be deemed to be forward-looking statements under federal securities laws, and Kendle intends that such forward-looking statements be subject to the safe-harbor created thereby. Such forward-looking statements include, but are not limited to Kendle's existing and planned growth and market penetration in the Asia Pacific region, including India. Kendle cautions that these statements are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements contained herein. Such factors include (a) fluctuation in the exchange rate of the U.S. dollar to other currencies; (b) the ability to set up and sustain growth entities in the above described regions; (c) changes in the markets for the company's service offerings; (d) changes in the market for customers' products; and (e) other risks as detailed from time to time in Kendle's SEC reports, including its Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and Annual Reports on Form 10-K.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Kendle Executive Dennis Hurley, DrSc to Present Keynote Address at DIA Latin American Congress 2007
2. Kendle Appoints Ken Hintze, PhD, Vice President, Global Clinical Safety & Pharmacovigilance
3. Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007
4. Kendle Appoints Industry Veteran to Lead Asia/Pacific Expansion
5. Kendle Invites You to Attend Its Fourth Quarter and Year End 2007 Earnings Conference Call and Webcast
6. Kendle Delivers Strong Growth in Revenues, New Business Authorizations and Operating Margin for Full-Year 2007; Announces Guidance for 2008
7. Kendle Promotes Simon S. Higginbotham to President; Appoints Alan J. Boyce as Chief Marketing Officer
8. Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008
9. Kendle Delivers Record Sales, Net Service Revenues and Earnings Per Share for Second Quarter 2008
10. Kendle to Present at 27th Annual J.P. Morgan Healthcare Conference
11. Kendle Revises Full Year 2008 Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... 2016 , ... Center for Autism and Related Disorders (CARD) Portland today announced ... disorder (ASD) and other developmental disabilities. The group, which is being launched with the ... the opportunity to share stories and advice, seek help, and continue their education on ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management programs available ... must find the one that works for them. When an inventor from Suisun City, ... worked and decided to share it with others. , He developed a prototype for ...
(Date:12/2/2016)... NY (PRWEB) , ... December 02, 2016 , ... More ... school and while 84 percent of parents report speaking with their child about sex ... and sexually transmitted diseases. , Mediaplanet is proud to announce the launch of its ...
(Date:12/2/2016)... Hawaii (PRWEB) , ... December 02, 2016 , ... ... 2016 at the Hyatt Regency Waikiki Beach Resort and Spa in Honolulu, offering ... in the field of pain management. , The demand for supplemental training ...
(Date:12/2/2016)... ... December 02, 2016 , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a ... No other wearable health technology on the market can deliver all that rejiva can. ... meaningful insights about their health than the usual heart rate and steps taken”, adds ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec 2, 2016 Research and ... Size, Share, Development, Growth and Demand Forecast to 2022" report to ... , , ... of $6 billion in 2015, and it is expected to grow at ... segment is expected to witness faster growth during the forecast period, a ...
(Date:12/2/2016)... CORDOBA, Spain , Dec. 2, 2016 ... additional natural sources apart from those derived from C. ... Córdoba, the Universita` di Napoli Federico II , ... have created the first comprehensive, critical, integrated and unified ... The article focuses on the remarkable chemical ...
(Date:12/2/2016)... Dec. 2, 2016  Maxor National Pharmacy Services, LLC ("Maxor"), ... Specialties, Inc. ("PSI").  The combination of Texas ... -based PSI bring together both company,s clinical expertise and ... payers an industry-leading specialty pharmacy. About Maxor ... , , ...
Breaking Medicine Technology: